Linked Life Data

15953008

Source:http://linkedlifedata.com/resource/pubmed/id/15953008

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15953008rdf:typepubmed:Citationlld:pubmed
pubmed-article:15953008lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:15953008lifeskim:mentionsumls-concept:C0001779lld:lifeskim
pubmed-article:15953008lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:15953008lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:15953008lifeskim:mentionsumls-concept:C0023449lld:lifeskim
pubmed-article:15953008lifeskim:mentionsumls-concept:C0040038lld:lifeskim
pubmed-article:15953008lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:15953008lifeskim:mentionsumls-concept:C1522326lld:lifeskim
pubmed-article:15953008lifeskim:mentionsumls-concept:C0442711lld:lifeskim
pubmed-article:15953008lifeskim:mentionsumls-concept:C1514983lld:lifeskim
pubmed-article:15953008lifeskim:mentionsumls-concept:C1511716lld:lifeskim
pubmed-article:15953008pubmed:issue6lld:pubmed
pubmed-article:15953008pubmed:dateCreated2005-6-14lld:pubmed
pubmed-article:15953008pubmed:abstractTextChildren with acute lymphoblastic leukaemia (ALL) are at increased risk for thromboembolism (TE). Identification of a susceptible population is crucial for effective thromboprophylaxis. However, the risk factors for ALL-associated TE are unclear. Concomitant asparaginase (ASP) and steroid therapy has been shown to increase the incidence of TE. Dana-Farber Cancer Institute (DFCI)-ALL protocols use a combination of ASP and steroids during the postinduction intensification phase when high-risk (HR) patients receive thrice the steroid-dose given to standard-risk (SR) patients. We studied prospectively assembled cohorts of children treated on two consecutive DFCI-ALL protocols to define the risk factors for symptomatic TE. Ten (11%) of 91 patients developed symptomatic TE; eight (seven HR) during intensification. Seven (44%) of 16 older patients (>/=10 years) compared with three of 75 (4%) younger patients developed TE (P < 0.0001). Nine of 35 (26%) HR and one of 56 (2%) SR patients developed TE (P = 0.0006). Gender, ALL-immunophenotype, steroid-type or ASP dosing schedule did not alter the risk but older age and HR-disease were factors predisposing to TE associated with DFCI-ALL protocols. Age-related risk may partly reflect the effect of ALL-risk stratification. Higher dose steroids combined with ASP may lead to an increased risk of TE in HR patients.lld:pubmed
pubmed-article:15953008pubmed:languageenglld:pubmed
pubmed-article:15953008pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15953008pubmed:citationSubsetIMlld:pubmed
pubmed-article:15953008pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15953008pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15953008pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15953008pubmed:statusMEDLINElld:pubmed
pubmed-article:15953008pubmed:monthJunlld:pubmed
pubmed-article:15953008pubmed:issn0007-1048lld:pubmed
pubmed-article:15953008pubmed:authorpubmed-author:AthaleUma HUHlld:pubmed
pubmed-article:15953008pubmed:authorpubmed-author:ChanAnthony...lld:pubmed
pubmed-article:15953008pubmed:authorpubmed-author:BarrRonald...lld:pubmed
pubmed-article:15953008pubmed:authorpubmed-author:CrowtherMarkMlld:pubmed
pubmed-article:15953008pubmed:authorpubmed-author:SicilianoSabr...lld:pubmed
pubmed-article:15953008pubmed:issnTypePrintlld:pubmed
pubmed-article:15953008pubmed:volume129lld:pubmed
pubmed-article:15953008pubmed:ownerNLMlld:pubmed
pubmed-article:15953008pubmed:authorsCompleteYlld:pubmed
pubmed-article:15953008pubmed:pagination803-10lld:pubmed
pubmed-article:15953008pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:meshHeadingpubmed-meshheading:15953008...lld:pubmed
pubmed-article:15953008pubmed:year2005lld:pubmed
pubmed-article:15953008pubmed:articleTitleThromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.lld:pubmed
pubmed-article:15953008pubmed:affiliationDivision of Hematology/Oncology, Department of Pediatrics, McMaster University, Hamilton, ON, Canada. athaleu@mcmaster.calld:pubmed
pubmed-article:15953008pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15953008pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15953008pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15953008lld:pubmed